These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 15087405)

  • 21. Simultaneous CD8+ T cell responses to multiple tumor antigen epitopes in a multipeptide melanoma vaccine.
    Valmori D; Dutoit V; Ayyoub M; Rimoldi D; Guillaume P; Liénard D; Lejeune F; Cerottini JC; Romero P; Speiser DE
    Cancer Immun; 2003 Oct; 3():15. PubMed ID: 14580186
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of identical TCRs in primary melanoma lesions and tumor free corresponding sentinel lymph nodes.
    Straten Pt; Dahl C; Schrama D; Pedersen LØ; Andersen MH; Seremet T; Bröcker EB; Guldberg P; Becker JC
    Cancer Immunol Immunother; 2006 May; 55(5):495-502. PubMed ID: 16001163
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cytotoxic T lymphocytes define multiple peptide isoforms derived from the melanoma-associated antigen MART-1/Melan-A.
    Jäger E; Höhn H; Karbach J; Momburg F; Castelli C; Knuth A; Seliger B; Maeurer MJ
    Int J Cancer; 1999 Jun; 81(6):979-84. PubMed ID: 10362148
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Large and dissimilar repertoire of Melan-A/MART-1-specific CTL in metastatic lesions and blood of a melanoma patient.
    Mandruzzato S; Rossi E; Bernardi F; Tosello V; Macino B; Basso G; Chiarion-Sileni V; Rossi CR; Montesco C; Zanovello P
    J Immunol; 2002 Oct; 169(7):4017-24. PubMed ID: 12244204
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prevalent role of TCR alpha-chain in the selection of the preimmune repertoire specific for a human tumor-associated self-antigen.
    Dietrich PY; Le Gal FA; Dutoit V; Pittet MJ; Trautman L; Zippelius A; Cognet I; Widmer V; Walker PR; Michielin O; Guillaume P; Connerotte T; Jotereau F; Coulie PG; Romero P; Cerottini JC; Bonneville M; Valmori D
    J Immunol; 2003 May; 170(10):5103-9. PubMed ID: 12734356
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vaccination with a Melan-A peptide selects an oligoclonal T cell population with increased functional avidity and tumor reactivity.
    Valmori D; Dutoit V; Schnuriger V; Quiquerez AL; Pittet MJ; Guillaume P; Rubio-Godoy V; Walker PR; Rimoldi D; Liénard D; Cerottini JC; Romero P; Dietrich PY
    J Immunol; 2002 Apr; 168(8):4231-40. PubMed ID: 11937585
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tumor-reactive, SSX-2-specific CD8+ T cells are selectively expanded during immune responses to antigen-expressing tumors in melanoma patients.
    Ayyoub M; Rimoldi D; Guillaume P; Romero P; Cerottini JC; Valmori D; Speiser D
    Cancer Res; 2003 Sep; 63(17):5601-6. PubMed ID: 14500401
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differences in phenotype and function between spontaneously occurring melan-A-, tyrosinase- and influenza matrix peptide-specific CTL in HLA-A*0201 melanoma patients.
    Maczek C; Berger TG; Schuler-Thurner B; Schultz ES; Hamann A; Dunbar PR; Cerundolo V; Steinkasserer A; Schuler G
    Int J Cancer; 2005 Jun; 115(3):450-5. PubMed ID: 15688371
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adoptive transfer of tumor-reactive Melan-A-specific CTL clones in melanoma patients is followed by increased frequencies of additional Melan-A-specific T cells.
    Vignard V; Lemercier B; Lim A; Pandolfino MC; Guilloux Y; Khammari A; Rabu C; Echasserieau K; Lang F; Gougeon ML; Dreno B; Jotereau F; Labarriere N
    J Immunol; 2005 Oct; 175(7):4797-805. PubMed ID: 16177129
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New generation vaccine induces effective melanoma-specific CD8+ T cells in the circulation but not in the tumor site.
    Appay V; Jandus C; Voelter V; Reynard S; Coupland SE; Rimoldi D; Lienard D; Guillaume P; Krieg AM; Cerottini JC; Romero P; Leyvraz S; Rufer N; Speiser DE
    J Immunol; 2006 Aug; 177(3):1670-8. PubMed ID: 16849476
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Peripheral burst of tumor-specific cytotoxic T lymphocytes and infiltration of metastatic lesions by memory CD8+ T cells in melanoma patients receiving interleukin 12.
    Mortarini R; Borri A; Tragni G; Bersani I; Vegetti C; Bajetta E; Pilotti S; Cerundolo V; Anichini A
    Cancer Res; 2000 Jul; 60(13):3559-68. PubMed ID: 10910069
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunization of stage IV melanoma patients with Melan-A/MART-1 and gp100 peptides plus IFN-alpha results in the activation of specific CD8(+) T cells and monocyte/dendritic cell precursors.
    Di Pucchio T; Pilla L; Capone I; Ferrantini M; Montefiore E; Urbani F; Patuzzo R; Pennacchioli E; Santinami M; Cova A; Sovena G; Arienti F; Lombardo C; Lombardi A; Caporaso P; D'Atri S; Marchetti P; Bonmassar E; Parmiani G; Belardelli F; Rivoltini L
    Cancer Res; 2006 May; 66(9):4943-51. PubMed ID: 16651452
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Novel approach to the characterization of melanoma associated-peptide-specific CTL lines from Japanese metastatic melanoma patients.
    Akiyama Y; Maruyama K; Tai S; Takikawa M; Ohshita C; Yamamoto A; Yamazaki N; Kiyohara Y; Yamaguchi K
    Int J Oncol; 2008 Sep; 33(3):433-41. PubMed ID: 18695871
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vivo activation of melanoma-specific CD8(+) T cells by endogenous tumor antigen and peptide vaccines. A comparison to virus-specific T cells.
    Speiser DE; Liénard D; Pittet MJ; Batard P; Rimoldi D; Guillaume P; Cerottini JC; Romero P
    Eur J Immunol; 2002 Mar; 32(3):731-41. PubMed ID: 11870617
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Overlapping peptides of melanocyte differentiation antigen Melan-A/MART-1 recognized by autologous cytolytic T lymphocytes in association with HLA-B45.1 and HLA-A2.1.
    Schneider J; Brichard V; Boon T; Meyer zum Büschenfelde KH; Wölfel T
    Int J Cancer; 1998 Jan; 75(3):451-8. PubMed ID: 9455808
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Umbilical cord blood T cells respond against the Melan-A/MART-1 tumor antigen and exhibit reduced alloreactivity as compared with adult blood-derived T cells.
    Merindol N; Grenier AJ; Caty M; Charrier E; Duval A; Duval M; Champagne MA; Soudeyns H
    J Immunol; 2010 Jul; 185(2):856-66. PubMed ID: 20543110
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ex vivo IFN-gamma secretion by circulating CD8 T lymphocytes: implications of a novel approach for T cell monitoring in infectious and malignant diseases.
    Pittet MJ; Zippelius A; Speiser DE; Assenmacher M; Guillaume P; Valmori D; Liénard D; Lejeune F; Cerottini JC; Romero P
    J Immunol; 2001 Jun; 166(12):7634-40. PubMed ID: 11390521
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sequential immune escape and shifting of T cell responses in a long-term survivor of melanoma.
    Yamshchikov GV; Mullins DW; Chang CC; Ogino T; Thompson L; Presley J; Galavotti H; Aquila W; Deacon D; Ross W; Patterson JW; Engelhard VH; Ferrone S; Slingluff CL
    J Immunol; 2005 Jun; 174(11):6863-71. PubMed ID: 15905528
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Melan-A/MART-1(51-73) represents an immunogenic HLA-DR4-restricted epitope recognized by melanoma-reactive CD4(+) T cells.
    Zarour HM; Kirkwood JM; Kierstead LS; Herr W; Brusic V; Slingluff CL; Sidney J; Sette A; Storkus WJ
    Proc Natl Acad Sci U S A; 2000 Jan; 97(1):400-5. PubMed ID: 10618430
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A shift in the phenotype of melan-A-specific CTL identifies melanoma patients with an active tumor-specific immune response.
    Dunbar PR; Smith CL; Chao D; Salio M; Shepherd D; Mirza F; Lipp M; Lanzavecchia A; Sallusto F; Evans A; Russell-Jones R; Harris AL; Cerundolo V
    J Immunol; 2000 Dec; 165(11):6644-52. PubMed ID: 11086110
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.